JenKem Technology offers large scale GMP manufacture of tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu (CAS# 1118767-16-0) with high purity (98%+) for drug modification.
Fatty acid side chains are known to improve patient compliance by to prolonging the half-life of Glucagon-like peptide-1 (GLP-1) receptor agonists used in the treatment of type II diabetes and obesity. Semaglutide is modified with a similar fatty acid side-chain which increases its affinity for albumin.
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu is a specialized peptide intermediate featuring a stearyl fatty acid side chain for drug conjugation. Synthesized via solid-phase peptide synthesis, it ensures precise coupling efficiency.
Store under inert atmosphere at -20°C to prevent hydrolysis. Handle with appropriate PPE due to potential sensitization risks; avoid direct contact during scale-up manufacturing.